Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial

CompletadoFase 3ClinicalTrials.gov

ID: NCT00641745Tipo: INTERVENTIONALInicio: 1 de mar de 2008Fin estimado: 1 de jul de 2010

Traducción no disponible, mostrando original

Resumen

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparator.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 75 YearsSexo: ALL

Criterios de inclusión

Subject is 18 to 75 years on the day of signing the consent form (age parameters may be restricted further per local requirements without protocol amendment).
Subject meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for a primary diagnosis of schizophrenia (including disorganized (295.10), paranoid (295.30), undifferentiated (295.90), catatonic (295.20), or residual (295.60) or schizoaffective disorder (295.70) subtypes.
Subject is not pregnant or nursing, and is not planning pregnancy within the projected duration of the study.
Subject will comply with the study procedures and outpatient visit requirements in the opinion of the investigator.
Subject voluntarily agrees to participate in the study by giving written informed consent.

Criterios de exclusión

To be excluded from entering this study if they fulfil any of the criteria below:
Subject has a chronic organic disease of the central nervous system (other than schizophrenia).
Subject has current clinically significant or history of, alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
In the opinion of the investigator, the subject has any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study.
Subject has participated in a study with an investigational compound or device within 30 days of signing informed consent.

Intervenciones

drug

Lurasidone HCl

40 - 120mg per day

drug

Risperidone

Ubicaciones

Fundación para el Estudio y Tratamiento de las Enf. Mentales

Capital Federal, BUE, Argentina

Clinica Privada Neuropsiquiatrica San Agustin

La Plata, BUE, Argentina

Resolution Psychopharmacology Research Institute

Mendoza, MEN, Argentina

CIAP

Rosario, SFE, Argentina

Sanatorio 'Prof. Leon S. Morra' S.A.

Córdoba, Argentina

Patrocinadores

PrincipalSumitomo Pharma America, Inc.

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Long-Term Safety, Tolerability, and Effectiveness of Lura... | EligiMed